It has been suggested that CB2 agonists can improve IBD by regulating macrophage polarization as demonstrated by the CB2 receptor agonist (JWH-133), which significantly reduced the level of M1 markers (TNF-α, IL-1β, and IL-12) in vitro. The gene discussed is CNR2; the disease is inflammatory bowel disease.